Get the Stockscreener App
1.85
0.54%
-0.00
After Hours:
1.84
-0.01
-0.54%
Proqr Therapeutics N V stock is traded at $1.85, with a volume of 268.14K.
It is down -0.54% in the last 24 hours and down -17.86% over the past month.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
See More
Previous Close:
$1.85
Open:
$1.86
24h Volume:
268.14K
Relative Volume:
0.64
Market Cap:
$149.03M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-4.8838
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-9.80%
1M Performance:
-17.86%
6M Performance:
-0.54%
1Y Performance:
-10.24%
1-Day Range:
$1.82
$1.87
1-Week Range:
$1.78
$2.055
52-Week Range:
$1.61
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.85 | 149.03M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 125.50B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.31B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.72B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.39B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.27B | 3.32B | -860.46M | -1.04B | -8.32 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Buy at Citigroup - Defense World
ProQR Therapeutics upgraded by Citigroup with a new price target - Quantisnow
ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by Citigroup - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Upgraded by Citigroup to Buy Rating - MarketBeat
Citigroup Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $4 -March 10, 2025 at 07:33 am EDT - Marketscreener.com
Citi raises ProQR stock rating to buy, sets $4 target By Investing.com - Investing.com Australia
Citi raises ProQR stock rating to buy, sets $4 target - Investing.com India
ProQR Therapeutics (PRQR) to Release Earnings on Wednesday - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
ProQR Therapeutics (PRQR) Expected to Announce Earnings on Wednesday - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of “Buy” from Brokerages - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) market cap touched US$250m last week, benefiting both individual investors who own 59% as well as institutions - Simply Wall St
Analyzing ProQR Therapeutics (NASDAQ:PRQR) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World
Head to Head Contrast: ProQR Therapeutics (NASDAQ:PRQR) versus Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World
Jones Trading sets ProQR stock Buy rating, $11 price target - MSN
This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Jones Trading Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Buy Recommendation - Nasdaq
Jones Trading sets ProQR stock Buy rating, $11 price target By Investing.com - Investing.com Australia
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17% - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Rating of "Buy" from Analysts - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Ballentine Partners LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Offer Predictions for PRQR FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on PRQR FY2025 Earnings - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update - MarketBeat
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock poised for growth - Investing.com
Oppenheimer Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Target Price from Analysts - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics' SWOT analysis: RNA-editing stock poised for clinical leap - Investing.com
ProQR Therapeutics’ (PRQR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
ProQR Therapeutics’ (PRQR) Buy Rating Reiterated at HC Wainwright - Defense World
ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70% - Simply Wall St
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):